With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising ...

Pfizer's stock rose 8.03%, despite bearish technicals and mixed analyst ratings. Technical indicators signal a bearish ...

Pfizer Inc. just made headlines by acquiring a promising biotech firm. The strategic move aims to enhance Pfizer's portfolio ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine ...

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major ...

Pfizer Inc. (NYSE:PFE) is one of the top cheap pharmaceutical stocks to buy now. On June 25, Pfizer Inc. (NYSE:PFE) announced ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...